Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jessica Merrill

Senior Editor

New York, NY
Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.

Latest From Jessica Merrill

FTC Is Taking A Tougher Stance On Pharma, A Deputy Director Explains Why

Rahul Rao, the deputy director of the FTC Bureau of Competition, discussed the agency’s thinking on recent pharma deals that it viewed as anti-competitive.

Deals Enforcement

FTC Is Taking A Tougher Stance On Pharma; A Deputy Director Explains Why

Deputy director of the Bureau of Competition Rahul Rao discussed the agency’s thinking on recent pharma deals that it viewed as anti-competitive.

Deals Enforcement

Pharma Facing Growing Risks From Geopolitics, Industry Leaders Warn

Industry leaders and experts at the Financial Times Pharma and Biotech Summit said the US relationship with China adds pressing risk to pharma.

Politics Manufacturing

Pharma Facing Growing Risks From Geopolitics, Industry Leaders Warn

Industry leaders and experts at the Financial Times Pharma and Biotech Summit said the US relationship with China adds pressing risk to pharma.

Politics Manufacturing

Underperforming Launches Reflect A New Era Of Payer Headwinds, IQVIA Says

US drug launches are underperforming historical metrics across nearly all therapeutic areas, according to IQVIA, which said limiting payer policies are the key factor.

Launches Market Access

Rapid Rise Or Slow Roll: How Long Does It Take To Become A Blockbuster?

Scrip analyzed data on top-selling drugs to see how long it takes to surpass $1bn in revenues and grow into $5bn and even $10bn brands.

Launches Commercial
See All
UsernamePublicRestriction

Register